Develops small molecule therapeutics that inhibit RNA-modifying proteins (RMPs) to target critical intracellular dependencies in multiple cancer types. This approach addresses the limitations of mutation-specific treatments by offering first-in-class and best-in-class candidates for patients with significant unmet medical needs.
Funding
$178M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MAFounders
Product
Problem
Many cancer treatments focus on mutation-specific vulnerabilities, which can limit their effectiveness and applicability across different cancer types. This approach leaves a significant unmet need for therapies that target more universal intracellular dependencies in cancer cells.
Solution
Accent Therapeutics develops small molecule therapeutics that inhibit RNA-modifying proteins (RMPs) to address critical intracellular dependencies common across multiple cancer types. By targeting RMPs, Accent's approach aims to overcome the limitations of mutation-specific treatments, offering potential first-in-class and best-in-class therapeutic candidates. These therapies are designed to disrupt fundamental processes within cancer cells, providing a broader impact on patient populations with significant unmet medical needs. The company's approach leverages expertise in RMP biology to identify and exploit these dependencies, leading to the development of high-value programs with far-reaching potential.
Target Audience
The primary target audience includes patients living with cancer, specifically those with significant unmet medical needs who may benefit from therapies that target universal intracellular dependencies rather than mutation-specific vulnerabilities.
Features
- Focus on inhibiting RNA-modifying proteins (RMPs)
- Development of small molecule therapeutics
- Targets critical intracellular dependencies in cancer cells
- Aims for both first-in-class and best-in-class therapeutic candidates
- Programs designed to benefit large patient populations